Pfizer Inc.

PFE

NYSE

24.6759

USD

+0.13(+0.51%)

As of today

Overview Financials Dividends Ratios Discussions Analysis

Pfizer Inc. fundamentals

Overview Income Statement Balance Sheet Cash Flow

Key ratios

P/E Ratio

13.06

Price/Book

1.58

Debt/Equity

69.67%

Return on Equity

11.94%

Dividend Yield

6.94%

EBITDA

18.13B

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Statements Highlights

AnnualQuarterly

Period Ending	Dec 31, 2020	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024
Total Revenue	41,651,000,000	81,288,000,000	100,330,000,000	59,553,000,000	63,627,000,000
Gross Profit	29,880,000,000	46,875,000,000	62,090,000,000	30,340,000,000	41,846,000,000
Operating Income	9,085,000,000	20,793,000,000	37,549,000,000	5,292,000,000	16,483,000,000
Net Income	9,159,000,000	22,147,000,000	31,365,000,000	2,133,000,000	8,020,000,000
Total Assets	154,229,000,000	181,477,000,000	197,206,000,000	226,501,000,000	213,396,000,000
Total Current Liabilities	25,920,000,000	42,671,000,000	42,138,000,000	47,794,000,000	42,995,000,000
Total Equity	63,473,000,000	77,463,000,000	95,917,000,000	89,288,000,000	88,497,000,000
Free Cash Flow	11,612,000,000	29,869,000,000	26,031,000,000	4,793,000,000	9,835,000,000
Cash from Operations	14,403,000,000	32,580,000,000	29,267,000,000	8,700,000,000	12,744,000,000
Cash from Investing	-4,271,000,000	-22,546,000,000	-15,783,000,000	-32,278,000,000	2,652,000,000
Cash from Financing	-9,649,000,000	-9,816,000,000	-14,834,000,000	26,066,000,000	-17,140,000,000
Net Change in Cash	475,000,000	158,000,000	-1,515,000,000	2,449,000,000	-1,810,000,000

Pfizer Inc.

PFE

24.6759

Pfizer Inc. fundamentals

Key ratios

Statements Highlights

Dividends

Analyst Recomendations